乳腺癌新辅助内分泌治疗的研究进展及展望

doi:10.19401/j.cnki.1007-3639.2022.07.008

摘要/Abstract

摘要：

新辅助内分泌治疗（neoadjuvant endocrine therapy,NET）代替新辅助化疗（neoadjuvant chemotherapy therapy,NCT）对于雌激素受体（estrogen receptor,ER）阳性乳腺癌患者而言是一种有效的临床治疗策略,可以使肿瘤降期,从而接受乳腺癌保乳手术并减少术后的辅助化疗。本文旨在就NET的患者选择、NET效果对比、NET持续时间、NET与NCT效果对比及联合使用、NET联合靶向治疗、机会之窗试验、疗效评估预后指标及NET后辅助治疗决策等最新研究进展进行综述。

关键词: 乳腺癌, 新辅助内分泌治疗, 预后

Abstract:

Neoadjuvant endocrine therapy (NET) instead of neoadjuvant chemotherapy (NCT) is an effective clinical strategy for estrogen receptor (ER)-positive breast cancer patients, which can reduce tumor stage, achieve breast-conserving surgery for breast cancer and reduce the need for adjuvant chemotherapy. This article aimed to review the latest research progress in several aeras: patient selection for NET, comparison of efficacy of NET, duration of NET, comparison and combined use of NET and NCT, NET combined with targeted therapy, window of opportunity trials, efficacy evaluation indicators and adjuvant therapy decision after neoadjuvant endocrine therapy.

Key words: Breast cancer, Neoadjuvant endocrine therapy, Prognosis

中图分类号:

R737.9

钱瑶(综述), 刘锋(审校). 乳腺癌新辅助内分泌治疗的研究进展及展望[J]. 中国癌症杂志, 2022, 32(7): 643-649.

QIAN Yao, LIU Feng. Research progress and prospects of neoadjuvant endocrine therapy for breast cancer[J]. China Oncology, 2022, 32(7): 643-649.

参考文献 52

[1]	SIEGEL R L, MILLER K D, GODING SAUER A, et al. Colorectal cancer statistics, 2020[J]. CA A Cancer J Clin, 2020, 70(3): 145-164. doi: 10.3322/caac.21601
[2]	CORTAZAR P, ZHANG L J, UNTCH M, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis[J]. Lancet, 2014, 384(9938): 164-172. doi: 10.1016/S0140-6736(13)62422-8
[3]	BERRY D A, CIRRINCIONE C, HENDERSON I C, et al. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer[J]. JAMA, 2006, 295(14): 1658-1667. doi: 10.1001/jama.295.14.1658
[4]	GIANNI L, PIENKOWSKI T, IM Y H, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial[J]. Lancet Oncol, 2012, 13(1): 25-32. doi: 10.1016/S1470-2045(11)70336-9
[5]	SCHNEEWEISS A, CHIA S, HICKISH T, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase Ⅱ cardiac safety study (TRYPHAENA)[J]. Ann Oncol, 2013, 24(9): 2278-2284. doi: 10.1093/annonc/mdt182
[6]	SIKOV W M, BERRY D A, PEROU C M, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage Ⅱ to Ⅲ triple-negative breast cancer: CALGB 40603 (Alliance)[J]. J Clin Oncol, 2015, 33(1): 13-21.
[7]	CARDOSO F, KYRIAKIDES S, OHNO S, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2019, 30(8): 1194-1220. doi: 10.1093/annonc/mdz173
[8]	GRADISHAR W J, ANDERSON B O, ABRAHAM J, et al. Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Cancer Netw, 2020, 18(4): 452-478.
[9]	BURSTEIN H J, CURIGLIANO G, THÜRLIMANN B, et al. Customizing local and systemic therapies for women with early breast cancer: the St. Gallen international consensus guidelines for treatment of early breast cancer 2021[J]. Ann Oncol, 2021, 32(10): 1216-1235. doi: 10.1016/j.annonc.2021.06.023
[10]	DOWSETT M, ELLIS M J, DIXON J M, et al. Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic[J]. NPJ Breast Cancer, 2020, 6: 21. doi: 10.1038/s41523-020-0168-9
[11]	NABHOLTZ J M, BUZDAR A, POLLAK M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group[J]. J Clin Oncol, 2000, 18(22): 3758-3767. doi: 10.1200/JCO.2000.18.22.3758
[12]	SMITH I E, DOWSETT M, EBBS S R, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial[J]. J Clin Oncol, 2005, 23(22): 5108-5116. doi: 10.1200/JCO.2005.04.005
[13]	CATALIOTTI L, BUZDAR A U, NOGUCHI S, et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative “Arimidex” Compared to Tamoxifen (PROACT) trial[J]. Cancer, 2006, 106(10): 2095-2103. doi: 10.1002/cncr.21872
[14]	MASUDA N, SAGARA Y, KINOSHITA T, et al. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial[J]. Lancet Oncol, 2012, 13(4): 345-352. doi: 10.1016/S1470-2045(11)70373-4
[15]	EIERMANN W, PAEPKE S, APPFELSTAEDT J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study[J]. Ann Oncol, 2001, 12(11): 1527-1532. doi: 10.1023/A:1013128213451
[16]	SEMIGLAZOV V, KLETSEL A, SEMIGLAZOV V, et al. Exemestane (E) vs tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1-2, T3N0-1, T4N0M0)[J]. J Clin Oncol, 2005, 23(16_suppl): 530. doi: 10.1200/jco.2005.23.16_suppl.530
[17]	ELLIS M J, SUMAN V J, HOOG J, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype: ACOSOG Z1031[J]. J Clin Oncol, 2011, 29(17): 2342-2349. doi: 10.1200/JCO.2010.31.6950
[18]	QUENEL-TUEUX N, DEBLED M, RUDEWICZ J, et al. Clinical and genomic analysis of a randomised phase Ⅱ study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer[J]. Br J Cancer, 2015, 113(4): 585-594. doi: 10.1038/bjc.2015.247
[19]	LEREBOURS F, RIVERA S, MOURET-REYNIER M A, et al. Randomized phase 2 neoadjuvant trial evaluating anastrozole and fulvestrant efficacy for postmenopausal, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer patients: results of the UNICANCER CARMINA 02 French trial (UCBG 0609)[J]. Cancer, 2016, 122(19): 3032-3040. doi: 10.1002/cncr.30143
[20]	MA C X, SUMAN V, LEITCH A M, et al. Abstract GS4-05: neoadjuvant chemotherapy (NCT) response in postmenopausal women with clinical stage Ⅱ or Ⅲ estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) resistant to endocrine therapy (ET) in the ALTERNATE trial (alliance A011106)[C]. American Association for Cancer Research, 2021.
[21]	ALLEVI G, STRINA C, ANDREIS D, et al. Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer[J]. Br J Cancer, 2013, 108(8): 1587-1592. doi: 10.1038/bjc.2013.151
[22]	CARPENTER R, DOUGHTY J C, CORDINER C, et al. Optimum duration of neoadjuvant letrozole to permit breast conserving surgery[J]. Breast Cancer Res Treat, 2014, 144(3): 569-576. doi: 10.1007/s10549-014-2835-8
[23]	FONTEIN D B, CHAREHBILI A, NORTIER J W, et al. Efficacy of six months neoadjuvant endocrine therapy in postmenopausal, hormone receptor-positive breast cancer patients: a phase Ⅱ trial[J]. Eur J Cancer, 2014, 50(13): 2190-2200. doi: 10.1016/j.ejca.2014.05.010
[24]	DIXON J M, RENSHAW L, MACASKILL E J, et al. Increase in response rate by prolonged treatment with neoadjuvant letrozole[J]. Breast Cancer Res Treat, 2009, 113(1): 145-151. doi: 10.1007/s10549-008-9915-6
[25]	SEMIGLAZOV V F, SEMIGLAZOV V V, DASHYAN G A, et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer[J]. Cancer, 2007, 110(2): 244-254. doi: 10.1002/cncr.22789
[26]	ALBA E, CALVO L, ALBANELL J, et al. Chemotherapy (CT) and hormonotherapy (HT) as neoadjuvant treatment in luminal breast cancer patients: results from the GEICAM/2006-03, a multicenter, randomized, phase-Ⅱ study[J]. Ann Oncol, 2012, 23(12): 3069-3074. doi: 10.1093/annonc/mds132
[27]	SPRING L M, GUPTA A, REYNOLDS K L, et al. Neoadjuvant endocrine therapy for estrogen receptor-positive breast cancer: a systematic review and meta-analysis[J]. JAMA Oncol, 2016, 2(11): 1477-1486. doi: 10.1001/jamaoncol.2016.1897
[28]	WANG Y L, HE L, SONG Y H, et al. The tumour response of postmenopausal hormone receptor-positive breast cancers undergoing different types of neoadjuvant therapy: a meta-analysis[J]. BMC Womens Health, 2020, 20(1): 17. doi: 10.1186/s12905-020-0879-y
[29]	GRADISHAR W J, MORAN M S, ABRAHAM J, et al. NCCN guidelines^® insights: breast cancer, version 4.2021[J]. J Natl Compr Canc Netw, 2021, 19(5): 484-493. doi: 10.6004/jnccn.2021.0023
[30]	SATO N, MASUDA N, MORIMOTO T, et al. Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks’ exemestane exposure in patients with estrogen receptor-positive breast cancer: a multicenter, open-label, phase Ⅱ study[J]. Cancer Med, 2019, 8(12): 5468-5481. doi: 10.1002/cam4.2423
[31]	MATSUNUMA R, WATANABE T, HOZUMI Y, et al. Preoperative concurrent endocrine therapy with chemotherapy in luminal B-like breast cancer[J]. Breast Cancer, 2020, 27(5): 819-827. doi: 10.1007/s12282-020-01077-0
[32]	SPRING L M, WANDER S A, ANDRE F, et al. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future[J]. Lancet, 2020, 395(10226): 817-827. doi: 10.1016/S0140-6736(20)30165-3
[33]	MA C X, GAO F, LUO J Q, et al. NeoPalAna: neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor-positive breast cancer[J]. Clin Cancer Res, 2017, 23(15): 4055-4065. doi: 10.1158/1078-0432.CCR-16-3206
[34]	HURVITZ S A, MARTIN M, PRESS M F, et al. Potent cell-cycle inhibition and upregulation of immune response with abemaciclib and anastrozole in neoMONARCH, phase Ⅱ neoadjuvant study in HR+/HER2- breast cancer[J]. Clin Cancer Res, 2020, 26(3): 566-580. doi: 10.1158/1078-0432.CCR-19-1425
[35]	COTTU P, D’HONDT V, DUREAU S, et al. Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer[J]. Ann Oncol, 2018, 29(12): 2334-2340. doi: 10.1093/annonc/mdy448
[36]	JOHNSTON S, PUHALLA S, WHEATLEY D, et al. Randomized phase Ⅱ study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor-positive early breast cancer: PALLET trial[J]. J Clin Oncol, 2019, 37(3): 178-189.
[37]	MILLER T W, REXER B N, GARRETT J T, et al. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer[J]. Breast Cancer Res, 2011, 13(6): 224. doi: 10.1186/bcr3039
[38]	SAURA C, HLAUSCHEK D, OLIVEIRA M, et al. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet Oncol, 2019, 20(9): 1226-1238. doi: 10.1016/S1470-2045(19)30334-1
[39]	BASELGA J, SEMIGLAZOV V, VAN DAM P, et al. Phase Ⅱ randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer[J]. J Clin Oncol, 2009, 27(16): 2630-2637. doi: 10.1200/JCO.2008.18.8391
[40]	ARNEDOS M, ROULLEAUX DUGAGE M, PEREZ-GARCIA J, et al. Window of opportunity trials for biomarker discovery in breast cancer[J]. Curr Opin Oncol, 2019, 31(6): 486-492. doi: 10.1097/CCO.0000000000000583
[41]	SERRANO D, LAZZERONI M, GANDINI S, et al. A randomized phase Ⅱ presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer[J]. Breast Cancer Res, 2013, 15(3): R47. doi: 10.1186/bcr3439
[42]	COHEN A L, FACTOR R E, MOONEY K, et al. POWERPIINC (preoperative window of endocrine therapy provides information to increase compliance) trial: changes in tumor proliferation index and quality of life with 7 days of preoperative tamoxifen[J]. Breast, 2017, 31: 219-223. doi: 10.1016/j.breast.2016.11.016
[43]	CROSHAW R, SHAPIRO-WRIGHT H, SVENSSON E, et al. Accuracy of clinical examination, digital mammogram, ultrasound, and MRI in determining postneoadjuvant pathologic tumor response in operable breast cancer patients[J]. Ann Surg Oncol, 2011, 18(11): 3160-3163. doi: 10.1245/s10434-011-1919-5
[44]	SYMMANS W F, PEINTINGER F, HATZIS C, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy[J]. J Clin Oncol, 2007, 25(28): 4414-4422. doi: 10.1200/JCO.2007.10.6823
[45]	NIELSEN T O, LEUNG S C Y, RIMM D L, et al. Assessment of Ki-67 in breast cancer: updated recommendations from the international Ki-67 in breast cancer working group[J]. J Natl Cancer Inst, 2020, 113(7): 808-819. doi: 10.1093/jnci/djaa201
[46]	ELLIS M J, TAO Y, LUO J Q, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics[J]. J Natl Cancer Inst, 2008, 100(19): 1380-1388. doi: 10.1093/jnci/djn309
[47]	STAFFORD A, WILLIAMS A, EDMISTON K, et al. Axillary response in patients undergoing neoadjuvant endocrine treatment for node-positive breast cancer: systematic literature review and NCDB analysis[J]. Ann Surg Oncol, 2020, 27(12): 4669-4677. doi: 10.1245/s10434-020-08905-9
[48]	WEISS A, WONG S, GOLSHAN M, et al. Patterns of axillary management in stages 2 and 3 hormone receptor-positive breast cancer by initial treatment approach[J]. Ann Surg Oncol, 2019, 26(13): 4326-4336. doi: 10.1245/s10434-019-07785-y
[49]	ELLIS M J, SUMAN V J, HOOG J, et al. Ki67 proliferation index as a tool for chemotherapy decisions during and after neoadjuvant aromatase inhibitor treatment of breast cancer: results from the American college of surgeons oncology group Z1031 trial (alliance)[J]. J Clin Oncol, 2017, 35(10): 1061-1069. doi: 10.1200/JCO.2016.69.4406
[50]	KANTOR O, WONG S, WEISS A, et al. Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer[J]. NPJ Breast Cancer, 2020, 6: 35. doi: 10.1038/s41523-020-00177-6
[51]	SMITH I, ROBERTSON J, KILBURN L, et al. Long-term outcome and prognostic value of Ki67 after perioperative endocrine therapy in postmenopausal women with hormone-sensitive early breast cancer (POETIC): an open-label, multicentre, parallel-group, randomised, phase 3 trial[J]. Lancet Oncol, 2020, 21(11): 1443-1454. doi: 10.1016/S1470-2045(20)30458-7
[52]	HARBECK N, GLUZ O, KUEMMEL S, et al. Abstract GS4-04: endocrine therapy alone in patients with intermediate or high-risk luminal early breast cancer (0-3 lymph nodes), recurrence score <26 and Ki-67 response after preoperative endocrine therapy: primary outcome results from the WSG-ADAPT HR+/HER2- trial[C]. American Association for Cancer Research, 2021.